sorafenib

FDA Drug Profile — sorafenib, Sorafenib, Nexavar

Drug Details

Generic Name
sorafenib
Brand Names
sorafenib, Sorafenib, Nexavar
Application Number
ANDA216073
Sponsor
Bayer AG
NDC Codes
8
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
SORAFENIB, SORAFENIB TOSYLATE

Indications and Usage

Sorafenib tablets are a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma(1.1) Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment (1.3) 1.1 Hepatocellular Carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive,differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.